Refine by
Nasal Discharge Equipment & Supplies
6 equipment items found
Manufactured by:Anatolia Geneworks based inSultanbeyli – Istanbul, TURKEY
Respiratory tract infections are typically divided into upper and lower respiratory tract infections which occur mainly in the nose, throat affecting upper respiratory system, windpipe, airways and lungs affecting lower respiratory system. From clinical point of view; symptoms such as nasal obstruction, nasal discharge, sore throat, cough, ...
Manufactured by:Imaginalis S.r.l based inSesto Fiorentino (FI), ITALY
With its HU and GT-30 series machines, Imaginalis has reached the highest levels of flat-panel CT technology, overcoming the boundaries that often come with scanning hard ...
Manufactured by:Imaginalis S.r.l based inSesto Fiorentino (FI), ITALY
With its HU and GT-30 series machines, Imaginalis has reached the highest levels of flat-panel CT technology, overcoming the boundaries that often come with scanning hard ...
Manufactured by:Neurent Medical based inOranmore, IRELAND
The NEUROMARK System is designed to treat symptoms of chronic rhinitis safely and effectively in the ENT physician’s office with a high degree of patient comfort. The system is engineered to gently apply controlled low-power Radio Frequency (RF) energy to target regions of the nasal cavity to disrupt the parasympathetic nerve signals and halt the inflammatory response, thereby eliminating ...
Manufactured by:Intersect ENT, Inc. based inMenlo Park, CALIFORNIA (USA)
SINUVA is the first and only FDA-approved stent for the treatment of nasal polyps in adult patients 18 years or older who have had ethmoid sinus surgery Are you still living with nasal polyps? Consider an alternative to another sinus surgery — SINUVA is a nonsurgical treatment option that can be placed in office. SINUVA delivers anti-inflammatory medicine directly to the nasal polyps, ...
Manufactured by:Lyra Therapeutics, Inc. based inWatertown, MASSACHUSETTS (USA)
Lyra’s lead product candidate, LYR-210, to treat chronic rhinosinusitis (CRS), an inflammatory disease of the paranasal sinuses. LYR-210 is an anti-inflammatory implantable drug matrix based upon Lyra’s XTreo™ platform designed to elute mometasone furoate consistently and locally to the inflamed mucosal tissue of surgically-naïve CRS patients for up to six months from a ...